Study of GST-HG131&141 Tablets Compared With Placebo in Patients With Chronic Hepatitis B

A randomized, double-blind, placebo-controlled Phase IIa clinical study to evaluate the safety and efficacy of GST-HG131/GST-HG141 tablets in patients with chronic hepatitis B

Inclusion Criteria: 1. Able to sign the informed consent form and fully understand the test content, process and possible adverse reactions. 2. Males and females aged 35-65 years(inclusive),able to complete research in accordance with test plan requirements. 3. Participants who have no childbearing plan in a year,and must agree to voluntarily use the contraceptive methods specified in the protocol from screening to 6 months after the last dose of the study. 4. Male body weight ≥ 50 kg, female body weight ≥ 45 kg, with a body mass index (BMI) of 18-30 kg/m2 (inclusive). 5. Participants who have received stable NA therapy for more than half a year， and have maintained the NA regimen for ≥3 months prior to Screening. 6. HBV DNA concentration must be adequately suppressed, defined as At least two tests within 28 days of the screening period (more than 1 week apart) with HBV DNA lower than LLOQ . 7. HBeAg negative, 100≤HBsAg ≤1500 IU/mL, serum Alanine aminotransferase (ALT)\